Provia Laboratories™ Expands its Stem Cell Portfolio to Amniotic Fluid, Chorionic Villi, and Placenta

Share Article

Provia Laboratories, a leader in cGMP stem cell processing, banking and manufacturing, executed an agreement to license Biocell Group’s technology for processing stem cells from Amniotic Fluid, Chorionic Villi, and Placenta for the US and Asian markets.

Just like antibiotics revolutionized medicine, I think... regenerative technologies will also revolutionize medicine and change our lives. -- Dr. Peter Verlander, CSO Provia

The proper collection, transport, processing, testing and preservation of stem cells is a crucial and significant part of the regenerative medicine value chain and stem cell therapy. The stem cell therapy market is estimated to exceed $180B in 2030 (Frost and Sullivan). In preparation for a future where stem cell therapies are a significant part of healthcare, companies have provided stem cell banking services from bone marrow and umbilical cord blood for over two decades. Thousands of patients have been treated with stem cells and well over a million families have privately preserved stem cells for their families own future use.

Provia Laboratories focuses on working with stem cells for autologous use (cells from you, for you). Under the brand Store-A-Tooth™, Provia offers a service to families who wish to preserve the stem cells in their children’s baby teeth and wisdom teeth for their future stem cell therapy needs. Mesenchymal stem cells, such as the stem cells found in teeth, are different than other stem cells as they differentiate into solid tissues like bone, cartilage, tendon, nerve and heart tissue. MSCs are the most published type of stem cell (BioInformant), more so than the controversial embryonic stem cells or even the hematopoietic stem cells found in bone marrow and umbilical cord blood.

Adding to its portfolio of mesenchymal stem cell (MSC) capabilities, Provia licensed the technologies developed by Biocell Center, a European group based in Italy with a subsidiary in Natick (MA), to process and preserve stem cells from amniotic fluid, chorionic villi, and placental tissue in the United States and Asian markets. Similar to MSCs found in dental pulp, they have strong proliferative capacity, and can differentiate into solid tissues.

"We are living at a very exciting time. I think we are getting to a place where we have the ability to take advantage of the different sources of stem cells and we are getting better at manipulating these stem cells," says Dr. Peter Verlander, Chief Scientific Officer of Provia.

These technologies allow Provia to offer customers additional opportunities to preserve their family's stem cells such as immediately after newborn delivery, during prenatal screening tests, and during amniocentesis. “At the core of Provia’s vision, we believe in helping individuals benefit from their own cells," says Howard Greenman, CEO of Provia Laboratories. He added, “We are delighted to work closely with the extraordinary team at Biocell. They are experts in the discovery and use of these cells, and working together with Biocell, we see a considerable market opportunity.”

The terms of the deal were not disclosed.

About Provia Laboratories, LLC
Provia Laboratories, LLC ( is a life sciences company headquartered in Littleton, MA which specializes in autologous (cells from you, for you) stem cells. Provia provides consumer services such as the ability for families to preserve the mesenchymal stem cells found inside teeth, Store-A-Tooth ( Store-A-Tooth is offered throughout dental and oral surgery offices throughout the United States and available through partners in Central American and Singapore. Additionally, Provia offers commercial clients cell processing services, bio storage and related products, as well as cellular research material.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ryan LeClair

Howard Greenman
since: 10/2009
Follow >
Like >
Provia Laboratories

Visit website